Literature DB >> 28573114

Otomastoiditis caused by Sphingomonas paucimobilis: case report and literature review.

Gabriel Nuncio Benevides1, Noely Hein2, Denise Swei Lo2, Angela Esposito Ferronato2, Selma Lopes Betta Ragazzi2, Cristina Ryoka Miyao Yoshioka2, Maki Hirose2, Debora Morais Cardoso2, Silvia Regina Dos Santos3, Alfredo Elias Gilio2,4.   

Abstract

Sphingomonas paucimobilis is an aerobic Gram-negative bacillus that, although rare in humans, most commonly infects immunocompromised and hospitalized patients. Among the 59 pediatric cases of S. paucimobilis infection reported in the literature, the most common diagnosis involves isolated bacteremia. These cases are related to sporadic or epidemic infections. Death related to this infection occurred in only one case. The authors report a case of an 11-year-old boy with the diagnosis of Sphingomonas paucimobilis otomastoiditis and a thorough review of the literature on this infection in pediatrics. The patient presented a 20-day history of fever, otalgia, otorrhea, and progressive retroauricular swelling with protrusion of the left ear; despite 15 days of amoxicillin regimen. His past medical history included chronic bilateral otitis media, but no cause of immunosuppression was found. A brain computed tomography scan showed left otomastoiditis associated with a large circumscribed fluid collection with deep involvement of the soft tissues of the temporal region, including the subperiosteal space. Blood tests showed neutrophilia and elevated C-reactive protein. Surgical manipulation of the cited collection drained a large amount of a fetid purulent secretion. Ceftazidime and clindamycin were empirically initiated. The outcome was favorable, with fever defervescence and resolution of the scalp deformation. Culture of the drained secretion was positive for S. paucimobilis. Ciprofloxacin was scheduled for a further 10 days after discharge. The follow-up showed complete recovery. As far as we know, this is the first case of S. paucimobilis otomastoiditis, complicated with subperiosteal abscess in an immunocompetent child. The authors call attention to the increasing number of reports on S. paucimobilis infection over the years, and therefore to the importance of this pathogen, which was previously underestimated.

Entities:  

Keywords:  Child; Gram-negative Bacterial Infections; Humans; Immunocompromised Host; Sphingomonas

Year:  2014        PMID: 28573114      PMCID: PMC5444394          DOI: 10.4322/acr.2014.024

Source DB:  PubMed          Journal:  Autops Case Rep        ISSN: 2236-1960


INTRODUCTION

Infection by Sphingomonas paucimobilis is rare. Although it occurs mostly in immunocompromised patients, cases of infected immunocompetents have been reported. We present a case of subperiosteal abscess due to a complicated otomastoiditis in an immunocompetent child. No previous case of subperiosteal abscess or otomastoiditis caused by S. paucimobilis has been reported. S. paucimobilis infection reports have been increasing in pediatric cases, encouraging us to conduct a literature review accompanied by the analysis of the clinical, demographic, and treatment data of the retrieved pediatric case report. We searched the PubMed and Google Scholar databases using the terms “Sphingomonas paucimobilis”, “Pseudomonas paucimobilis,” “Sphingomonas,” and “paucimobilis”; checking out the references of each elected article for any paper that could have been missed. All available publications related to S. paucimobilis infection in children, from 0 to 18 years, were retrieved. To the best of our knowledge, this is the first review of pediatric infections due to these bacteria.

CASE REPORT

An 11-year-old boy was brought to the emergency department with a 20-day history of fever, otalgia, otorrhea, and progressive retroauricular swelling, displacing the left ear anteriorly and downwards (Figure 1).
Figure 1

3D reformation of the mastoid computed tomography showing the bulging tumoral mass displacing the left ear downwards and anteriorly.

He was previously prescribed amoxicillin for 15 days without improvement. He lived in an orphanage and his HIV serology was negative. He had a previous diagnosis of bilateral chronic otitis media, but no other comorbidity was present. A computed tomography (CT) scan was performed (Figure 2) showing left otomastoiditis associated with a large fluid collection involving the subperiosteal layer of the temporal bone and the surrounding soft tissues, measuring 10.1 × 6.0 × 2.2 cm. Blood tests showed a white blood count of 22.4 × 103mm3 (reference value [RV]: 4.5‑11.0 × 103/mm3)(neutrophils 81.2%; RV: 40-70%) and C-reactive protein of 142 mg/L (RV: < 5 mg/L).
Figure 2

Computed tomography of the mastoid. A and B - Coronal plane. C and D - Axial plane. D represents the bone window. Arrow 1 shows the erosion of the temporal bone; arrow 2 the external ear canal. The abscess is connected with the mastoid do to the erosion of the temporal bone. The collection involved all soft tissues of the temporal region limited externally by the skin.

Surgical intervention on the retroauricular mass found a large amount of fetid and purulent secretion, a sample of which was sent off for microbiology studies. Ceftazidime and clindamycin were empirically started. The outcome was successful immediately after the surgical procedure, with fever defervescence, and normalization of blood tests. After 8 days of incubation, the culture of purulent secretion was positive for S. paucimobilis, but unfortunately, the antibiogram could not be tested because the bacteria in the culture media was no longer available. Therefore, based on literature data, we decided to maintain the initial antibiotic regimen and discharged the patient on the tenth day of hospitalization, scheduling 10 more days of oral ciprofloxacin to be taken at home.

METHODS

We searched PubMed, Google Scholar and LILACS databases using the terms “Sphingomonas paucimobilis”, “Pseudomonas paucimobilis”, “Sphingomonas” and “paucimobilis”. The references of each selected article were checked out in order to avoid missing any other paper. From a total of 1699 articles, 20 were related to Sphingomonas paucimobilis infection in children and adolescents up to 18 years, and therefore were selected.

DISCUSSION

The genus Sphingomonas comprises 13 Gram-negative, non-fermentative, non-sporing, oxidase- and catalase-positive bacilli. Sphingomonas paucimobilis is slightly motile (thus paucimobilis) and forms yellow pigmented colonies in blood agar.1 It was believed that S. paucimobilis was the only specimen of clinical importance; however, recently Sphingomonas mucosissima and Sphingomonas adhesiva also have been related to human infection.2,3 These bacilli are ubiquitous in nature (especially in water and soil) and in nosocomial environments causing mild-to-severe community and nosocomial illnesses.1,4 First described by Holmes et al.5 in the 1970s as Pseudomonas paucimobilis, it was later reclassified as Sphingomonas paucimobilis in accordance with phylogenetic data by Yabuuchi et al.6 in the 1990s. Curiously, this bacteria was related to the death of the coral reef on the coast of Florida, USA.7 The full-automated microbiology identification systems like “autoSCAN-W/A” and the “Vitek GNI1,” may fail to identify some genera and species. Sung et al.8 showed that the major misidentified bacteria were the Gram-negative non-fermentative, especially S. paucimobilis in the autoSCAN-W/A system. In 1979, the case of an infected leg ulcer of a Japanese seaman in Australia, was the first reported human infection.9 In 1981, the first pediatric colonization case by this bacteria was reported,10 but only in 1988 did Tiffany and Kline11 describe the first pediatric case of S. paucimobilis infection related to a brain abscess in a 6-year-old boy after a head trauma. Since then, the reports on this infection has increased, totaling 59 reported cases in pediatrics to date. Before 1980, no S. paucimobilis infection in children was reported. One case was reported between 1981 and 1990, three cases between 1991 and 2000, 28 cases between 2001 and 2010, and 27 cases between 2011 and March 2014, including ours (Figure 3). Despite the reported cases of infections, numerous cases of colonization by this bacteria were also published.10,12,13
Figure 3

The number of reported pediatric cases of S. paucimobilis infection from 1980 until March 2014.

Table 1 lists all elected cases of pediatric S. paucimobilis infection retrieved in our review. Table 2 summarizes the demographic and clinical data. The median age was 4.4 years (ranging from 3 days to 17 years); 22 cases occurred during the neonatal period (37.3%). The observed male:female ratio was 1.7:1.0. Hospital-acquired disease was identified in 66.1% and previous comorbidities were present in all of those patients.
Table 1

Cases of S. paucimobilis infection in children, since the first publication in 1988 until March 2014

ConditionAgeGenderUnderlying conditionsTherapyCountrySource of outbreakNumber of patientsReference
CR-BSI
14y
-
Acute myeloid leukemia
Trimethoprim-Sulfamethoxazole
Saudi Arabia
Hospital
1
14
Osteomyelitis/ septic arthritis
16y
M
ALL
Amikacin/Ceftazidime
United Kingdom
**
1
15
Bacteremia
<1y
F
Chylothorax
Not described
Korea
Hospital
1
16
Bacteremia
2y
F
Aplastic anemia
Not described
Korea
Hospital
1
16
Bacteremia
8y
M
ALL
Not described
Korea
Hospital
1
16
Bacteremia
<1y
M
Neonatal sepsis
Not described
Korea
Hospital
1
16
CAPD peritonitis
14y
F
End-stage renal disease
Not described
Korea
Hospital
1
16
CR-BSI
1y
M
Anaplastic ependymoma
Not described
Korea
Hospital
1
16
CR-BSI
17y
M
Ewing sarcoma
Not described
Korea
Hospital
1
16
CR-BSI
10d
M
Prematurity/RDS
Not described
Taiwan
Hospital
1
17
Bacteremia
6y
F
Lymphoma
Imipenem/Teicoplanin
Turkey
Hospital
1
18
Bacteremia
5y
F
Neuroblastoma
Imipenem/Teicoplanin
Turkey
Hospital
1
18
Bacteremia
11y
M
Non-Hodgkin lymphoma
Imipenem/Teicoplanin
Turkey
Hospital
1
18
Bacteremia
3y
M
Acute myeloid leukemia
Imipenem/Teicoplanin
Turkey
Hospital
1
18
Pneumonia
5y
M
None
Ampicillin-Sulbactam
Taiwan
Community
1
19
UTI
5m
M
None
Ampicillin/Gentamicin
Taiwan
Community
1
19
Bacteremia*
0m
-
Prematurity
Not described
Turkey
Hospital
13
20
Bacteremia
2y
M
None
Ceftriaxone
India
Community
1
20
Bacteremia
7y
F
None
Cefuroxime
Turkey
Community
1
22
Bacteremia
1m
F
None
Ampicillin/Sulbactam
Turkey
Community
1
22
Bacteremia
15y
F
None
Cefotaxime
Turkey
Community
1
22
Bacteremia
1y
F
None
Cefuroxime
Turkey
Community
1
22
Bacteremia
8y
F
Neutropenia-ALL
Piperacillin/Tazobactam
Turkey
Hospital
1
22
Bacteremia
8d
F
Prematurity
Meropenem/Vancomycin
Turkey
Hospital
1
22
Bacteremia
12y
F
None
Piperacillin/Tazobactam
Turkey
Hospital
1
22
Bacteremia
27d
F
None
Meropenem
Turkey
Hospital
1
22
Bacteremia
3y
M
None
Cefotaxime
Turkey
Community
1
22
Bacteremia
12y
M
PSAGN
Cefuroxime
Turkey
Community
1
22
Bacteremia
18d
M
Prematurity
Ampicillin/Amikacin
Turkey
Community
1
22
Bacteremia
9y
M
Down syndrome
Meropenem/Vancomycin
Turkey
Community
1
22
Bacteremia
1m
M
None
Ampicillin/Sulbactam
Turkey
Community
1
22
Bacteremia
3d
M
None
Ampicillin/Amikacin
Turkey
Community
1
22
Bacteremia
23d
M
None
Ampicillin/Sulbactam
Turkey
Community
1
22
Bacteremia
1y
M
Imperforate anus
Ceftazidime
Turkey
Hospital
1
22
Bacteremia
23d
M
Duodenal atresia
Cefotaxime/Amikacin
Turkey
Hospital
1
22
Bacteremia
11y
M
None
Meropenem
Turkey
Hospital
1
22
Bacteremia
4y
M
Neutropenia-ALL
Piperacillin/Tazobactam
Turkey
Hospital
1
22
Bacteremia
5y
M
Neutropenia-ALL
Piperacillin/Tazobactam
Turkey
Hospital
1
22
CNS infection
10y
M
None
Cefotaxime/Vancomycin
Turkey
Community
1
22
CR-BSI
4y
M
Burn injury
Meropenem/Amikacin
Turkey
Hospital
1
22
CR-BSI
10y
F
Neutropenia-ALL
Piperacillin/Tazobactam
Turkey
Hospital
1
22
UTI
4m
F
None
Cefuroxime
Turkey
Community
1
22
Bacteremia
1y
M
Cardiopathy-Down syndrome
Piperacillin/Tazobactam
Turkey
Hospital
1
4
Otomastoiditis
11y
M
None
Ceftazidime/Clindamycin/Ciprofloxacin
Brazil
Community
1
Present Study
Bacteremia
6y
M
None
Cefotaxime/Gentamicin
Spain
Community
1
23
Cervical adenitis
8y
M
None
Ampicillin
Spain
Community
1
23
Brain abscess6aFNoneAmpicillin/ChloramphenicolUSACommunity111

ALL = acute lymphoblastic leukemia); CAPD = continuous ambulatory peritoneal dialysis; CNS = central nervous system; CR-BSI = catheter-related bloodstream infection; PSAGN = steroid-induced immunosuppression due to glomerulonephritis; RDS = respiratory distress syndrome; UTI = urinary tract infection;

= case of fatal outcome;

= the author could not define if it was a community or hospital infection.

Table 2

Demographic and clinical characteristics of S. paucimobilis infection in children—data of the literature review

ConditionNo. of casesMean age (range)Gender(ratio) M:FHealthy/previouscomorbidity(no. of cases)Nosocomial/Community-acquired(No. of cases)
Isolated bacteremia*
44
3.1y (0-15y)
1.5:1
13/31
31/13
CR-BSI
6
8.3y (0-17y)
4:1
0/6
6/0
UTI
2
4.5m (4-5m)
1:1
2/0
0/2
CAPD peritonitis
1
14y
0:1
0/1
1/0
Cervical adenitis
1
8y
1:0
1/0
0/1
CNS infection
1
10y
1:0
1/0
1/0
CNS abscess
1
6y
0:1
1/0
0/1
Osteomyelitis/septic arthritis
1
16y
1:0
0/1
***
Pneumonia
1
5y
1:0
1/0
0/1
Otomastoiditis**
1
11y
1:0
1/0
0/1
Total594.4y (0-17y)1.7:120/3939/20

CAPD = continuous ambulatory peritoneal dialysis; CNS = central nervous system; CR-BS = catheter-related bloodstream infection; UTI = urinary tract infection;

= case of fatal outcome;

= present study;

= the author could not define if it was nosocomial or community acquired infection.

ALL = acute lymphoblastic leukemia); CAPD = continuous ambulatory peritoneal dialysis; CNS = central nervous system; CR-BSI = catheter-related bloodstream infection; PSAGN = steroid-induced immunosuppression due to glomerulonephritis; RDS = respiratory distress syndrome; UTI = urinary tract infection; = case of fatal outcome; = the author could not define if it was a community or hospital infection. CAPD = continuous ambulatory peritoneal dialysis; CNS = central nervous system; CR-BS = catheter-related bloodstream infection; UTI = urinary tract infection; = case of fatal outcome; = present study; = the author could not define if it was nosocomial or community acquired infection. The most common infection site was primary bacteremia (74.6%) followed by catheter-related bloodstream infection (10.2%), urinary tract infection (3.4%) and one case (1.7%) of each of the following: peritonitis related to continuous ambulatory peritoneal dialysis, cervical adenitis, central nervous system (CNS) infection, CNS abscess, osteomyelitis/septic arthritis, pneumonia, and otomastoiditis. Prematurity was the commonest associated comorbidity observed in 16 cases (41%); 13 cases were associated with malignancy (33%), out of which all were from the hematopoietic system; 2 cases (5.2%) occurred in children with Down syndrome, 2 cases (5.2%) with gut malformations, and 6 cases associated with other isolated diseases. S. paucimobilis has been isolated from blood, sputum, urine, wound, ascitic liquid, cerebrospinal fluid, synovial liquid, and purulent secretion (brain, bone, and mastoid).11,14-23 Some studies associate S. paucimobilis outbreaks with contamination of the nosocomial environment; however, none of the reviewed papers demonstrated the same strain of the contamination with those of the infection site.17,18,20,24 Consequently, the endogenous source of the infection is the current theory on the route of infection.17,23 In addition, infection was also related to hospitalization, indwelling devices, and previous comorbidities, but our own case and other recent studies show that community-acquired infections are more prevalent than previously thought.19,25 Although Gram-negative infections frequently result in significant morbidity and mortality, S. paucimobilis infections seem to show a low rate of complications and a favorable prognosis.16,19,21,24,25 Only one case of pediatric death has been reported related to S. paucimobilis infection, which occurred in a premature neonate with septic shock.20 It is supposed that this low virulence is caused by the presence of atypical lipopolysaccharide in the outer membrane, a deficiency of bacterial endotoxins, and a different enzyme profile.6,26,27 S. paucimobilis antibiotic susceptibility varies according to the study. In general, they are significantly resistant to cephalosporin, especially the third generation, as well as to penicillins. Lin et al.19 showed that all isolated bacteria produced β-lactamase; however, other studies showed a resistance to cephalosporins of around 20%.21,22 There is also reported resistance to aminoglycosides, quinolones, trimethoprim, and sulfamethoxazole, and lesser to carbapenems.4,14-18,21,22 In previous studies, the recommendation of initial antibiotic therapy was a third generation cephalosporin added to an aminoglycoside; however, more current studies suggest that carbapenems or quinolones show a better susceptibility pattern.4,16,17,22 Despite supposed initial inappropriate antibiotic therapy reported in some cases of the literature, none presented any complication due to the delayed institution of the appropriate treatment.21,22 Since antibiotic resistance varies, treatment should be guided by the susceptibility test results of each case.4,16 In conclusion, S. paucimobilis is an emerging pathogen in pediatric patients, and not just a contaminant of the hospital environment. The nosocomial or community-acquired infection is related to previous comorbidities, which are mostly associated with immunosuppression due to prematurity and malignancy. However, previously healthy patients may also be involved. Compared with other Gram-negative bacteria, S paucimobilis, characteristically present low virulence; however, death has been reported already in one pediatric case. Notwithstanding the resistance to beta-lactam antibiotics, the first choice of treatment consists in carbapenems or quinolones.
  24 in total

1.  Clinical features and treatment outcomes of infections caused by Sphingomonas paucimobilis.

Authors:  Hae Suk Cheong; Yu Mi Wi; Soo Youn Moon; Cheol-In Kang; Jun Seong Son; Kwan Soo Ko; Doo Ryeon Chung; Nam Yong Lee; Jae-Hoon Song; Kyong Ran Peck
Journal:  Infect Control Hosp Epidemiol       Date:  2008-10       Impact factor: 3.254

Review 2.  Mixed flora brain abscess with Pseudomonas paucimobilis after a penetrating lawn dart injury.

Authors:  K K Tiffany; M W Kline
Journal:  Pediatr Infect Dis J       Date:  1988-09       Impact factor: 2.129

3.  [Sphingomonas paucimobilis].

Authors:  María A Martínez; Alfredo Ovalle
Journal:  Rev Chilena Infectol       Date:  2013-02       Impact factor: 0.520

4.  Outbreak of Sphingomonas paucimobilis septicemia in a neonatal intensive care unit.

Authors:  Mehmet Mutlu; Gülçin Bayramoglu; Gürdal Yilmaz; Berna Saygin; Yakup Aslan
Journal:  Indian Pediatr       Date:  2011-05-30       Impact factor: 1.411

5.  Osteomyelitis and secondary septic arthritis caused by Sphingomonas paucimobilis.

Authors:  R M Charity; A F Foukas
Journal:  Infection       Date:  2005-04       Impact factor: 3.553

6.  Nosocomial infections caused by Sphingomonas paucimobilis: clinical features and microbiological characteristics.

Authors:  P R Hsueh; L J Teng; P C Yang; Y C Chen; H J Pan; S W Ho; K T Luh
Journal:  Clin Infect Dis       Date:  1998-03       Impact factor: 9.079

7.  Nosocomial outbreak of Sphingomonas paucimobilis bacteremia in a hemato/oncology unit.

Authors:  Abdullah Kilic; Zeynep Senses; A Emin Kurekci; Hakan Aydogan; Kenan Sener; Erol Kismet; A Celal Basustaoglu
Journal:  Jpn J Infect Dis       Date:  2007-11       Impact factor: 1.362

8.  Septic shock caused by Sphingomonas paucimobilis bacteremia in a patient with hematopoietic stem cell transplantation.

Authors:  K A Al-Anazi; S Abu Jafar; A M Al-Jasser; A Al-Shangeeti; N A Chaudri; M D Al Jurf; F I Al-Mohareb
Journal:  Transpl Infect Dis       Date:  2007-07-01       Impact factor: 2.228

9.  Sphingomonas paucimobilis infections in children: 24 case reports.

Authors:  Nuri Bayram; Ilker Devrim; Hurşit Apa; Gamze Gülfidan; Hande Namal Türkyılmaz; Ilker Günay
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-06-05       Impact factor: 2.576

10.  Sphingomonas mucosissima Bacteremia in patient with sickle cell disease.

Authors:  Emmanouil Angelakis; Véronique Roux; Didier Raoult
Journal:  Emerg Infect Dis       Date:  2009-01       Impact factor: 6.883

View more
  2 in total

Review 1.  The Gram-Negative Bacilli Isolated from Caves-Sphingomonas paucimobilis and Hafnia alvei and a Review of Their Involvement in Human Infections.

Authors:  Mihaela Ileana Ionescu; Dan Ștefan Neagoe; Alexandra Marioara Crăciun; Oana Teodora Moldovan
Journal:  Int J Environ Res Public Health       Date:  2022-02-17       Impact factor: 3.390

2.  Dangerous passengers: multidrug-resistant bacteria on hands and mobile phones.

Authors:  P F Martina; M Martinez; C K Centeno; M VON Specht; J Ferreras
Journal:  J Prev Med Hyg       Date:  2019-12-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.